Purple Biotech Ltd (PPBT)

Purple Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.24	8.72	7.4	14.49	15.03	10.89
Short-Term Investments	0.87	0.86	1.12	0.92	17.08	36.31
Cash & Short-Term Investments	6.11	9.57	8.52	15.41	32.11	47.2
Cash Growth	3.14%	12.32%	-44.69%	-52.01%	-31.96%	-18.35%
Prepaid Expenses	-	0.16	0.28	0.21	1	1.01
Other Current Assets	0.49	0.14	0.11	0.17	0.15	0.27
Total Current Assets	6.59	9.87	8.91	15.79	33.26	48.47
Property, Plant & Equipment	0.22	0.35	0.29	0.47	0.68	0.9
Long-Term Investments	-	-	-	-	-	0.19
Other Intangible Assets	7.36	7.36	27.84	28.04	20.68	20.48
Other Long-Term Assets	-	-	-	-	-	0.16
Total Assets	14.17	17.57	37.04	44.3	54.62	70.2

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.49	2.07	1.46	3.53	2.13	1.47
Accrued Expenses	0.93	1.37	1.2	3.46	4.72	2.56
Current Portion of Leases	0.13	0.24	0.18	0.19	0.19	0.2
Other Current Liabilities	0.23	4.07	1.15	2.52	0.01	0.02
Total Current Liabilities	1.78	7.75	3.99	9.7	7.06	4.25
Long-Term Leases	-	-	-	0.16	0.32	0.55
Pension & Post-Retirement Benefits	0.17	0.16	0.14	0.14	0.15	0.29
Total Liabilities	1.95	7.91	4.13	10.01	7.52	5.09

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Additional Paid-In Capital	155.83	152.48	147.63	133.18	126.41	123.95
Retained Earnings	-170.72	-171.08	-144.69	-137.45	-117.57	-95.91
Comprehensive Income & Other	27.16	28.31	29.92	38.48	38.08	36.78
Total Common Equity	12.27	9.71	32.86	34.21	46.91	64.83
Minority Interest	-0.06	-0.06	0.05	0.09	0.19	0.28
Shareholders' Equity	12.21	9.66	32.91	34.3	47.1	65.11
Total Liabilities & Equity	14.17	17.57	37.04	44.3	54.62	70.2

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.13	0.24	0.18	0.35	0.52	0.75
Net Cash (Debt)	5.97	9.33	8.34	15.06	31.6	46.45
Net Cash Growth	2.67%	11.86%	-44.62%	-52.34%	-31.98%	-18.38%
Net Cash Per Share	0.00	0.01	0.03	0.07	0.17	0.26
Filing Date Shares Outstanding	2,172	1,859	529.64	265.58	207.87	178.26
Total Common Shares Outstanding	2,172	1,859	517.13	252.38	184.82	178
Working Capital	4.81	2.11	4.92	6.09	26.2	44.22
Book Value Per Share	0.01	0.01	0.06	0.14	0.25	0.36
Tangible Book Value	4.91	2.35	5.02	6.16	26.23	44.35
Tangible Book Value Per Share	0.00	0.00	0.01	0.02	0.14	0.25

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 23, 2026

Data Sources Report a data error